Unlock the Potential of PI3Kγ Inhibition with Eganelisib (IPI-549)
A potent and selective PI3Kγ inhibitor driving advancements in immuno-oncology and disease research.
Get a Quote & SampleProduct Core Value
Selective PI3Kγ Inhibitor Compound 1693758-51-8
Eganelisib, also known as IPI-549, stands as a highly potent and selective phosphoinositide-3-kinase gamma (PI3Kγ) inhibitor. This compound is instrumental in immuno-oncology research, offering a targeted approach to modulate immune responses within the tumor microenvironment and to treat inflammatory and autoimmune diseases. Its robust in vitro and in vivo data underscore its potential as a key therapeutic candidate.
- Explore the precise mechanism of action of PI3K gamma inhibitor IPI-549 in modulating cellular signaling pathways.
- Discover the drug properties of Eganelisib, focusing on its selectivity and efficacy in preclinical models.
- Learn why researchers choose to buy IPI-549 PI3K inhibitor for advanced studies in cancer and immunology.
- Understand the role of selective PI3K inhibitors for research in developing novel therapeutic strategies.
Key Advantages
Unparalleled Selectivity
Eganelisib exhibits over 100-fold selectivity against other lipid and protein kinases, making it a precise tool for targeted PI3Kγ research, crucial for understanding its role in immune response modulation.
In Vivo Efficacy
Demonstrated ability to significantly reduce neutrophil migration and inhibit tumor growth in preclinical models, highlighting its potential as a leading immuno-oncology clinical candidate.
Favorable Pharmacokinetics
The compound boasts excellent oral bioavailability and a favorable pharmacokinetic profile, allowing for potent and selective PI3Kγ inhibition in vivo, which is critical for drug development.
Key Applications
Immuno-Oncology Research
Investigate how IPI-549 can reshape the tumor microenvironment and enhance anti-tumor immunity, a key area for effective cancer treatment.
Inflammatory Disease Treatment
Understand the role of PI3Kγ in inflammatory pathways and explore Eganelisib's potential to develop novel therapies for conditions like autoimmune diseases.
Drug Discovery and Development
Utilize this advanced pharmaceutical intermediate as a building block or lead compound in the discovery of new therapeutic agents.
Biochemical Research Tool
Leverage the high purity and defined properties of IPI-549 for in-depth biochemical and cellular assays to elucidate complex biological processes.